(Stock Code 股份代號: 0532) ANNUAL REPORT 年 報 2024 The WKK Group ANNUAL REPORT 年報 2024 | C T | O | N | E | N | T | S | | --- | --- | --- | --- | --- | --- | --- | | Corporate Information 公司資料 | | | | | | 3 | | Chairman's Statement 主席報告書 | | | | | | 4 | | Financial Highlights 財務摘要 | | | | | | 8 | | Five Years Financial Summary 五年財務概要 | | | | | | 9 | | Biographical Details of Directors and Senior Management 董事及高層管理人員個人資料 | | | | | | 11 | | Report of the Directors 董事會報告書 | | | | | | 21 | | Corporate Governance Rep ...

Huayu Expressway Group Limited 華昱高速集團有限公司 ( 於開曼群島註冊成立的有限公司 ) 股份代號 : 1823 2024 年報 目錄 | 公司資料 | 2 | | --- | --- | | 財務概要 | 3 | | 主席報告 | 4 | | 管理層討論與分析 | 5 | | 企業管治報告 | 12 | | 環境、社會及管治報告 | 23 | | 董事及高級管理層 | 43 | | 董事會報告書 | 45 | | 獨立核數師報告 | 57 | | 綜合損益表 | 63 | | 綜合損益及其他全面收益表 | 65 | | 綜合財務狀況表 | 66 | | 綜合權益變動表 | 68 | | 綜合現金流量表 | 69 | | 財務報表附註 | 71 | 華昱高速集團有限公司 1 目錄 公司資料 董事會 執行董事 陳陽南 （主席） 符捷頻 （行政總裁） 劉寶華 獨立非執行董事 林漢權 朱健宏 胡列格 董事委員會 審核委員會 朱健宏 （主席） 胡列格 林漢權 提名委員會 林漢權 （主席） 胡列格 符捷頻 薪酬委員會 胡列格 （主席） 朱健宏 符捷頻 公司秘書 冼家敏 HKICPA, F ...

目錄 | 2 | 公司資料 | | --- | --- | | 4 | 財務及營運數據摘要 | | 5 | 公司簡介 | | 6 | 主席報告 | | 8 | 管理層討論與分析 | | 25 | 董事及高級管理層 | | 31 | 董事會報告 | | 50 | 企業管治報告 | | 67 | 環境、社會及管治報告 | | 93 | 獨立核數師報告 | | 98 | 綜合損益及其他全面收益表 | | 99 | 綜合財務狀況表 | | 101 | 綜合權益變動表 | | 102 | 綜合現金流量表 | | 104 | 綜合財務報表附註 | | 161 | 財務概要 | 162 釋義 公司資料 公司名稱 盛禾生物控股有限公司 董事 執行董事 張峰先生 （主席） 殷劉松博士 （首席執行官兼首席科學官） 姜曉玲女士 （副總裁） 非執行董事 范融奎先生 獨立非執行董事 陳向榮先生 馮嵐女士 史錄文先生 審核委員會 陳向榮先生 （主席） 馮嵐女士 史錄文先生 薪酬委員會 授權代表 張峰先生 黃凱婷女士 審計師 德勤 • 關黃陳方會計師行 執業會計師 註冊公眾利益實體審計師 香港 金鐘道88號 太古廣場一期35樓 法律顧問 ...

年報 2024 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的中小型公司提供一個上市的市場。有意投資 的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波動風險，同時 無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照《聯交所的GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關福田股份有限公司（「本 公司」）的資料；本公司的董事（「董事」）願就本報告的資料共同及個別地承擔全部責任。各董事在作出一切合理查詢 後，確認就其所知及所信，本報告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何事 項，足以令致本報告或其所載任何陳述產生誤導。 目錄 2 公司資料 4 主席報告 7 管理層討論及分析 1 ...

蓬 力 普 控 股 有 限 公 司 DALIPAL HOLDINGS LIMITED (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) Stock code 股份代號 : 1921 ANNUAL REPORT 年報 2024 CONTENTS 目 錄 | 4 | Corporate Information | | --- | --- | | | 公司資料 | | 8 | Glossary | | | 詞彙 | | 14 | Chairman's Statement | | | 主席報告 | | 17 | Directors and Senior Management Profiles | | | 董事及高級管理層簡介 | | 26 | Management Discussion and Analysis | | | 管理層討論及分析 | | 41 | Report of the Board of Directors | | | 董事會報告 | | 63 | Corporate Governance Repo ...

Forward Fashion (International) Holdings Company Limited （於開曼群島註冊成立的有限公司） 股份代號 : 2528 2024 年報 Forward Fashion (International) Holdings Company Limited Annual Report 2024 年報 目錄 | | 頁次 | | --- | --- | | 公司資料 | 2 | | 主席致辭 | 3 | | 管理層討論及分析 | 4 | | 董事及高級管理層 | 12 | | 企業管治報告 | 17 | | 董事會報告 | 31 | | 獨立核數師報告 | 53 | | 綜合損益及其他全面收益表 | 59 | | 綜合財務狀況表 | 61 | | 綜合權益變動表 | 63 | | 綜合現金流量表 | 65 | | 綜合財務報表附註 | 67 | | 五年財務資料 | 148 | 二零二四年年報 尚晉（國際）控股有限公司 公司資料 董事會 執行董事 范榮庭先生 （主席） 陳幸儀女士 （行政總裁） 陳漢榮先生 方日明先生 范麗君女士 獨立非執行董事 余振球先生 伍鑑津先生 ...

LOCATIONS OF THE GROUP'S COKING COAL MINES 本集團的焦煤礦所在地 Xingwu Coal Mine 興無煤礦 Jinjiazhuang Coal Mine 金家莊煤礦 Zhaiyadi Coal Mine Liulin County 柳林縣 寨崖底煤礦 CORPORATE PROFILE SHOUGANG FUSHAN RESOURCES GROUP LIMITED is one of the most sizable integrated coking coal corporations in CENTRAL-WESTERN CHINA. Taking Shanxi Province as its major investment base, it is principally engaged in MINING OF COKING COAL, PRODUCTION AND SALES OF RAW AND CLEAN COKING COAL. The Group has three premium operating coking coal mines and t ...

ANNUAL REPORT 年 報 2024 CONTENTS 目錄 | 2 | Company Profile | | --- | --- | | | 公司簡介 | | 3 | Chairman's Statement | | | 主席報告 | | 6 | Management Discussion and Analysis | | | 管理層討論及分析 | | 24 | Corporate Governance Report | | | 企業管治報告 | | 48 | Environmental, Social and Governance Report | | | 環境、社會及管治報告 | | 98 | Biographical Details of Directors and Senior Management | | | 董事及高級管理人員的履歷詳情 | | 107 | Report of the Directors | | | 董事會報告 | | 131 | Independent Auditor's Report | | | 獨立核數師報告書 | | 140 | Consolidated Sta ...

China Greenland Broad Greenstate Group Company Limited 中國綠地博大綠澤集團有限公司 (於開曼群島註冊成立的有限公司) 股份代號：1253 年報 2024 2024 ANNUAL REPORT China Greenland Broad Greenstate Group Company Limited 中國綠地博大綠澤集團有限公司 (Incorporated in the Cayman Islands with limited liability) Stock code : 1253 Chi n a Gre e nla n d Bro o a d Gre e n state Gro u p C m p a n y Limite d 中國綠地博大綠澤集團有限 公 司 ANNUAL REP O R T 年 報 2 0 2 4 博 博 博採眾長 Eclectic 大 大 大有作為 Accomplishment 精 深 精 深 精益求精 Excelsior 深生不息 Continuous 目錄 | 公司資料 | 02 | | --- | --- | | 財務摘要 ...

Innovation and Product Development - Akeso, Inc. has developed over 50 innovative projects in various fields, including oncology, autoimmune, and metabolic diseases, with 71 products approved for market and 1 product under NMPA review[10]. - The company has 12 products in Phase III clinical trials and 12 products in Phase I/II clinical trials, with 15 potential first-in-class or best-in-class bispecific/multispecific antibodies[10]. - The company aims to become a leading global biopharmaceutical enterprise by focusing on innovative R&D, establishing a world-class production system, and continuously expanding its commercial network[10]. - Three new products were approved for market launch, and two new indications were approved for existing products[20]. - A total of 24 products are undergoing global clinical research, with over 25 registration/Phase III clinical studies conducted[20]. - The company has submitted new indication applications for five products, indicating ongoing innovation[20]. - The approval of the self-developed drugs Inusimab (PCSK9) and Yiruoqi (the first self-developed IL-12/IL-23 in China) marks the official launch of the company's non-oncology specialty drug business[21]. - The company is building an international leading advantage in tumor immunotherapy with over 40 indications explored through clinical therapy and Phase III clinical studies[21]. - The company is focused on global market expansion and innovative drug development, enhancing its long-term growth foundation[20]. - The company continues to strengthen its global development momentum through source innovation[20]. - The company aims to continue developing new drugs and integrating global resources, focusing on the global development and commercialization of Kadooni and Yiwosi[24]. - The company is strategically advancing Yidafang in various cancers, with ongoing Phase III trials for colorectal cancer and pancreatic cancer initiated[45]. - The company has multiple IND-stage projects in development, indicating a robust pipeline for future growth[105]. Financial Performance - The total revenue for the year ending December 31, 2024, was RMB 2,123.9 million, a decrease of 53.08% compared to RMB 4,526.3 million for the year ending December 31, 2023[25]. - The commercial sales revenue after deducting distribution costs was RMB 2,002.4 million, an increase of 24.88% from RMB 1,603.5 million in 2023, driven by the continued growth of Kadooni (卡度尼利) and the positive sales contribution from Yiwosi (依沃西) after its approval in May 2024[28]. - The gross profit for the year ending December 31, 2024, was RMB 1,834.9 million, a decrease of 58.23% from RMB 4,393.0 million in the previous year[26]. - The company recorded a loss of RMB 501.1 million for the year ending December 31, 2024, compared to a profit of RMB 1,942.4 million for the year ending December 31, 2023[27]. - The company's research and development expenses for the year ending December 31, 2024, were RMB 1,187.7 million, a decrease of 5.29% from RMB 1,254.0 million in the previous year, due to enhanced internal clinical team capabilities[85]. - The sales and marketing expenses for the year ending December 31, 2024, were RMB 1,001.8 million, reflecting a 12.51% increase from RMB 890.4 million in the previous year, driven by accelerated commercialization efforts[87]. - The financial cost for the year ending December 31, 2024, was RMB 68.3 million, a decrease of 21.53% from RMB 87.0 million in the previous year, primarily due to lower borrowing rates[89]. - The company has short-term and long-term loans totaling RMB 3,941.6 million, with RMB 535.5 million due within the next year[91]. - As of December 31, 2024, the company's current assets totaled RMB 8,691.6 million, with cash and cash equivalents amounting to RMB 7,343.9 million, an increase of RMB 2,449.4 million from RMB 4,894.4 million as of December 31, 2023[90]. Clinical Trials and Approvals - Kadooni has received approval for second-line treatment of cervical cancer and has initiated 28 clinical trials across 20 indications, including gastric, lung, and liver cancers[29]. - Yiwosi has shown significant positive results in three Phase III clinical trials, establishing its clinical and commercial value in the NSCLC field[23]. - Kadooni's sNDA for first-line treatment of unresectable locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma was approved in September 2024[31]. - The company is advancing over 12 Phase III clinical trials and more than 20 Phase II clinical trials for Yiwosi globally, positioning itself as a leader in the market[23]. - The company is advancing multiple Phase III clinical trials for Cardunili, focusing on major indications such as lung cancer and gastric cancer, with ongoing patient enrollment[36][37]. - The AK117 (CD47) trial for head and neck squamous cell carcinoma is the first Phase III registration trial for a CD47 product in solid tumors, with data presented at the 2024 ESMO[48]. - The Phase III trial (AK112-303/HARMONi-2) for Yidafang against Pembrolizumab in treating PD-L1 positive NSCLC achieved positive results, with data presented at the 2024 WCLC[42]. Market Strategy and Expansion - The commercial development journey will begin in 2025, focusing on the hospital market[21]. - The company is committed to upgrading its commercial system to seize opportunities in the rapidly changing Chinese innovative drug industry[73]. - The company has a strategic focus on expanding its oncology and immunology product lines, with substantial investment in clinical trials[108]. - The company aims to leverage its cornerstone drugs, Kadcyla® and Ivosidenib, to cover a broader market space through extensive combination therapies[64]. - The company has established an exclusive sales agreement for monoclonal antibodies with a projected annual cap of RMB 3,000 million for sales and promotion fees by December 31, 2024, and RMB 6,000 million for sales of monoclonal products[150]. Workforce and Operations - The total number of employees as of December 31, 2024, is 3,035, an increase from 2,778 in 2023, reflecting a growth of approximately 9.3%[70]. - The workforce in clinical research has increased to 700 from 679, showing a focus on enhancing research capabilities[70]. - The production, quality assurance, and quality control department has expanded to 814 employees, up from 687, indicating growth in operational support[70]. - The sales and marketing team has grown to 816 employees, an increase from 788, reflecting an emphasis on market expansion[70]. - The company has maintained stable employee relations without any significant strikes or labor disputes affecting business activities[142]. Governance and Compliance - The company is committed to compliance with relevant laws and regulations, with no significant violations reported for the year ending December 31, 2024[141]. - The company has implemented internal controls to ensure compliance with listing rules regarding related party transactions[157]. - The board of directors includes Dr. Xia Yu as the Chairman, President, and CEO, and Dr. Li Baiyong as the Executive Vice President and Chief Scientific Officer[137]. - The company has undergone changes in its board composition, with several appointments and resignations effective June 30, 2024[137]. - The company has a dedicated company secretary with over 17 years of experience in providing corporate services[134]. Financial Commitments and Investments - The company completed the acquisition of a 35% stake in 康融東方 for RMB 267.4 million on February 8, 2024, making it a wholly-owned subsidiary[95]. - The company's capital commitments as of December 31, 2024, were RMB 734.0 million, down from RMB 770.0 million a year earlier, primarily due to ongoing construction of production facilities[98]. - The net proceeds from the 2024 March placement were utilized according to previously disclosed intentions, ensuring transparency in fund allocation[106]. - The company plans to accelerate clinical trials for multiple products, including PD-1/CTLA-4 and CD47, with significant funding allocated for these initiatives[105]. Community Engagement and Corporate Responsibility - The group made charitable donations of approximately RMB 41.8 million during the year, an increase from RMB 23.6 million in 2023[179]. - The company is committed to environmental sustainability and adheres to relevant environmental protection laws and regulations[140]. - The company has a strong focus on resource efficiency, waste reduction, and energy savings in its operations[140].